MBX Biosciences, Inc. (MBX)
NASDAQ: MBX · Real-Time Price · USD
29.04
-2.93 (-9.16%)
At close: Apr 28, 2026, 4:00 PM EDT
29.05
+0.01 (0.03%)
Pre-market: Apr 29, 2026, 4:21 AM EDT
MBX Biosciences Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Net Income | -86.97 | -61.92 | -32.56 | -26.14 |
| Depreciation & Amortization | 0.35 | 0.24 | 0.16 | 0.06 |
| Loss (Gain) From Sale of Assets | - | - | 0.07 | - |
| Loss (Gain) From Sale of Investments | -3.61 | -2.93 | -1.04 | -0.03 |
| Stock-Based Compensation | 8.68 | 5.22 | 2.04 | 0.31 |
| Other Operating Activities | 0.03 | 0.11 | 0.1 | 1.39 |
| Change in Accounts Payable | -2.46 | 3.93 | 0.41 | 0.67 |
| Change in Other Net Operating Assets | 4.03 | 0.67 | -1.15 | 0.62 |
| Operating Cash Flow | -79.95 | -54.68 | -31.98 | -23.12 |
| Capital Expenditures | -1.93 | -0.87 | -0.13 | -0.44 |
| Investment in Securities | -81.78 | -159.72 | -30.8 | -10.97 |
| Investing Cash Flow | -83.71 | -160.6 | -30.93 | -11.41 |
| Short-Term Debt Issued | - | - | - | 10 |
| Total Debt Issued | - | - | - | 10 |
| Net Debt Issued (Repaid) | - | - | - | 10 |
| Issuance of Common Stock | 190.36 | 174.95 | 0.74 | 0.03 |
| Other Financing Activities | -0.77 | -4.34 | -0.03 | -0.46 |
| Financing Cash Flow | 189.59 | 234.1 | 69.22 | 46.06 |
| Net Cash Flow | 25.94 | 18.83 | 6.31 | 11.53 |
| Free Cash Flow | -81.88 | -55.56 | -32.11 | -23.56 |
| Free Cash Flow Per Share | -2.24 | -5.22 | -31.52 | -35.33 |
| Levered Free Cash Flow | -52.44 | -33.27 | -20.56 | - |
| Unlevered Free Cash Flow | -52.44 | -33.27 | -20.56 | - |
| Change in Working Capital | 1.58 | 4.6 | -0.74 | 1.29 |
Source: S&P Capital IQ. Standard template.
Financial Sources.